PARP1 and cancer: Interestingly, cancer stem cells (CSCs) displayed higher expression of PD‐L1 compared to nonstem cell cancer cells, which might contribute to the long‐term survival improvement by immunotherapy425 and make ICIs a potential strategy to overcome resistance of CSCs to PARP inhibitors.426